Incyte (INCY) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of $0.78. This compares to earnings of $0.99 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -333.33%. A quarter ago, it was expected that this specialty drugmaker would post earnings of $0.88 per share when it actually produced earnings of $0.64, delivering a surprise of -27.27%.Over the last four quarters, the company has surp ...

财务业绩 - 公司第二季度总收入同比增长9%，超过10.44亿美元[1] - 公司第二季度总GAAP收入为10.44亿美元，同比增长9%[45] - 公司总体业绩亏损，净亏损4.45亿美元[98] - 公司调整后净亏损3.96亿美元，每股调整后亏损1.82美元[104] 主要产品收入 - Jakafi产品净收入为7.06亿美元，同比增长3%，总患者数增长7%[2] - Jakafi产品收入增长3%，主要由于销量增长9%[47] - Opzelura产品净收入为1.22亿美元，同比增长52%[3] - Opzelura产品收入增长52%，主要由于新患者数量和复购量增加[47] - Minjuvi/Monjuvi产品收入增长136%，主要由于2024年2月收购了该产品的全球独家权利[47] - Jakavi版税收入增长10%[48] 费用情况 - GAAP研发费用增长184%，主要由于收购Escient公司支付的670.9百万美元研发费用[59] - GAAP销售及管理费用增长8%，主要由于收购Escient公司相关的补偿费用[60] - GAAP和非GAAP经营利润均大幅下降，主要由于收购Escient公司相关费用的影响[62] - 由于收购Escient公司相关的非税务抵免费用，公司本季度税收费用为5,480万美元[63] 现金流和股票回购 - 截至2024年6月30日和2023年12月31日,现金、现金等价物和有价证券总额分别为14亿美元和37亿美元,2024年现金、现金等价物和有价证券的减少主要由于2024年6月完成的20亿美元股票回购以及支付给Escient股东的7.83亿美元现金对价[64] - 2024年6月,Incyte完成了20亿美元的股票回购,反映了公司对未来业务前景的信心、商业组合和临床开发管线的实力[65] 业务发展 - 公司宣布将重点关注具有高潜力影响力的临床项目,包括皮肤科和免疫项目povorcitinib、MRGPRX2和MRGPRX4,以及肿瘤和造血方面的项目[7] - 公司将停止进一步开发口服小分子PD-L1抑制剂、LAG-3单克隆抗体、TIM-3单克隆抗体和LAG-3xPD-1双特异性抗体[8] - 公司完成收购Escient Pharmaceuticals,获得其临床阶段项目EP262和EP547[11] - 公司与中国医药系统控股有限公司达成合作,授权其在大中华区和东南亚开发和商业化JAK1抑制剂povorcitinib[12] 产品获批情况 - Jakafi获批适应症包括多发性骨髓纤维化、多血症vera和急性移植物抗宿主病等[73] - Opzelura获批适应症包括非节段性白癜风和轻中度特应性皮炎[74,75] - Monjuvi获批适应症为弥漫大B细胞淋巴瘤[77,78] - Pemazyre获批适应症为胆管癌和骨髓/淋巴细胞肿瘤[79,80,81,82] - Iclusig获批适应症为慢性髓性白血病和Ph+急性淋巴细胞白血病[85,86] - Zynyz获批适应症为转移性或复发性局部晚期默克尔细胞癌[88] 其他 - 公司从合作伙伴获得2500万美元里程碑付款[106] - 公司支付4.14万美元和1.41万美元给合作伙伴的前期对价和里程碑费用[106] - 公司完成了对Escient公司的收购,相关费用为3.40亿美元[103] - 公司承担了270万美元的MorphoSys过渡成本[103] - 公司权益投资的已实现和未实现收益为1.39亿美元[103]

We expect Incyte Corporation (INCY) to surpass expectations when it reports second-quarter 2024 results on Jul 30, before the opening bell.Let’s see how things have shaped up for the quarter to be reported.Factors to NoteIncyte primarily derives product revenues from the sales of its lead drug, Jakafi (ruxolitinib), in the United States and other marketed drugs.An increase in the sales of Jakafi, a first-in-class JAK1/JAK2 inhibitor in all approved indications (polycythemia vera, myelofibrosis and refractor ...

Incyte (INCY) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on July 30, 2024, might help the stock move higher if these key numbers are better than expectatio ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Incyte (INCY) and Myriad Genetics (MYGN) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasi ...

Shares of Incyte (INCY) were on the upward trajectory in the past three months. The stock has risen 19.6% in this time frame compared with the industry's growth of 8.9%. Last week, Incyte announced that it granted restricted stock unit awards (RSUs), representing an aggregate of 14,577 shares of the company's common stock, and stock option awards to purchase an aggregate of 18,149 shares of the company's common stock to 27 new employees. The company's shares rose following this announcement. Image Source: Z ...

LaylaBird Incyte (NASDAQ:INCY) is one of the leaders in the global Janus kinase inhibitors market. Investment thesis Over the past month and a half, the company's share price has increased by more than 20%, reflecting grown optimism among institutional and retail investors following its $750 million acquisition of Escient Pharmaceuticals and the announcement in mid-May that its Board of Directors had authorized a $2 billion share buyback plan. Source: TradingView In my estimation, the acquisition has al ...

Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Malignant Mesothelioma - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. A comprehensive report has been released offering detailed insights into the advancements within the Malignant Mesothelioma treatment pipeline, encompassing over 20 pharmaceutical companies and more than 20 drugs in development. This critical analysis presents a hopeful outlook for stakeholders and patients affected by Malignant Mesothelioma, a rare but ...

A month has gone by since the last earnings report for Incyte (INCY) . Shares have added about 7.5% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Incyte due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Incyte Q1 Earnings & Revenues Fall Shy of Estimates Incyte r ...

UKRAINE - 2021/05/24: In this photo illustration, Incyte Corp logo of a pharmaceutical company is ... [+] seen displayed on a smartphone and pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesThe stock price of Incyte Incyte , a biopharmaceutical company, trades at $58 per share, about 43% below its peak level of $100 seen in January 2021. INCY stock was trading at around $76 in early June 2022, just before the Fed started increas ...